OptiNose Corp (OPTN) - Koefisien utang jangka dawa marang modal

OptiNose Corp - logo grafis emiten OPTN

The price history of OptiNose, Inc. (OPTN) demonstrates the dynamics of an asset whose metrics reach 0.00. The business relies on partnerships with retail chains to expand the distribution of nasal products without mergers. An exclusive, patent-protected drug delivery mechanism generates revenue. Production efficiency is driven by the implementation of robots in assembly and packaging lines, which significantly reduces personnel costs.

OptiNose Inc (OPTN): Utang jangka dawa marang ekuitas saka 04.07.2022 nganti 31.05.2025
Produk mawa merek OptiNose, Inc.

Investing in OptiNose, Inc. (OPTN) requires a rigorous fundamental analysis of its liability structure. This ratio compares loans with maturities exceeding one year against equity to determine the degree of financial leverage. By analyzing the long-term debt-to-equity profile, an investor assesses the company's reliance on external borrowing. For a pharmaceutical monopolist with a protected patent system, such a metric confirms the ability to maintain high margins without excessive debt pressure. A low debt load indicates high quality of the issuer's capital.

Analisis perusahaan pesaing

Haleon PLC - Kewajiban jangka dawa marang ekuitas|Utang jangka dawa marang modal KVUE|VRNA (Verona Pharma Inc.) - Koefisien utang jangka dawa marang modal|Utang jangka dawa marang modal MENS (Jyong Biotech Ltd)|Utang jangka dawa marang modal ligand.com LGND|AMRX - Utang jangka dawa marang ekuitas|Koefisien utang jangka dawa marang modal PRGO (Perrigo Company PLC)|Alvotech Corp (ALVO) - Utang jangka dawa marang ekuitas|Rasio utang jangka dawa marang ekuitas Liquidia Inc.|GLPG (Galapagos NV) - Utang jangka dawa marang modal|Utang jangka dawa marang modal anipharmaceuticals.com|Rasio utang jangka dawa marang ekuitas MNKD (MannKind)|AMPH (Amphastar Pharmaceuticals Inc) - Koefisien utang jangka dawa marang modal|Utang jangka dawa marang ekuitas Pacira PCRX|ARS Corp (SPRY) - Kewajiban jangka dawa marang modal|TBPH: Rasio utang jangka dawa marang ekuitas|aquestive.com - Rasio silihan jangka dawa marang modal|SCPH: Utang jangka dawa marang modal|Tectonic Therapeutic - Koefisien utang jangka dawa marang modal|TNXP (Tonix Pharmaceuticals Inc.) - Utang jangka dawa marang modal|Kewajiban jangka dawa marang modal SXT China SXTC|Utang jangka dawa marang ekuitas Eupraxia Pharmaceuticals (EPRX)|BHST (bioharvest.com) - Koefisien utang jangka dawa marang modal|Utang jangka dawa marang ekuitas eXoZymes EXOZ|Oramed (ORMP) - Kewajiban jangka dawa marang modal|ENTX - Utang jangka dawa marang ekuitas|Kewajiban jangka dawa marang ekuitas HYFT|ABVC (ABVC BioPharma) - Rasio utang jangka dawa marang ekuitas|CPIX: Rasio silihan jangka dawa marang modal|QNTM (Quantum BioPharma) - Utang jangka dawa marang modal|FibroGen Inc (FGEN) - Rasio tanggungan utang jangka dawa marang modal|Utang jangka dawa marang ekuitas Telomir Pharma (TELO)|ranitherapeutics.com - Rasio utang jangka dawa marang modal|Utang jangka dawa marang ekuitas Synergy CHC SNYR|Rallybio Corp (RLYB) - Kewajiban jangka dawa marang modal|LEXX - Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka dawa marang modal Pulmatrix Inc PULM|PTHL: Utang jangka dawa marang modal|Kewajiban jangka dawa marang modal Aptorum Group (APM)|Rasio utang jangka dawa marang ekuitas LYRA|IBO: Koefisien utang jangka dawa marang modal|Utang jangka dawa marang modal TNFA|Rasio tanggungan utang jangka dawa marang modal cbdmd.com|Utang jangka dawa marang ekuitas PainReform Limited PRFX|CYTO: Rasio utang jangka dawa marang modal|Lipella Pharmaceuticals - Utang jangka dawa marang modal|pieris.com (PIRS) - Rasio utang jangka dawa marang ekuitas|PROC (Procaps) - Rasio utang jangka dawa marang ekuitas|PTPI - Rasio tanggungan utang jangka dawa marang modal|Utang jangka dawa marang ekuitas Qilian International Holding Group Limited|Kewajiban jangka dawa marang modal ACELYRIN Inc. SLRN|Utang jangka dawa marang ekuitas TFF Pharmaceuticals (TFFP)